Covid-19 vaccine doses administered in India cross 510 mn: Health min

The cumulative COVID-19 vaccine doses administered in the country has crossed the landmark of 51 crore, the Union health ministry said on Monday.

Covid-19 vaccine doses administered in India cross 510 mn: Health min
Press Trust of India New Delhi
2 min read Last Updated : Aug 09 2021 | 9:59 PM IST

The cumulative COVID-19 vaccine doses administered in the country has crossed the landmark of 51 crore, the Union health ministry said on Monday.

More than 49 lakh (49,06,273) doses have been administered on Monday, according to the 7 pm provisional report.

The ministry said 26,66,611 vaccine doses were administered as first dose and 4,59,352 vaccine doses given as second dose in the age group 18-44 years on Monday.

Cumulatively, 17,95,70,348 persons in the age group 18-44 years across all states and union territories have received their first dose and 1,24,91,475 have received their second dose since the start of the third phase of the vaccination drive.

Five states -- Madhya Pradesh, Gujarat, Rajasthan, Maharashtra and Uttar Pradesh -- have administered more than 1 crore cumulative doses of COVID-19 vaccine in the age group 18-44 years.

Also, Andhra Pradesh, Assam, Chhattisgarh, Delhi, Haryana, Jharkhand, Kerala, Telangana, Himachal Pradesh, Odisha, Punjab, Uttarakhand and West Bengal have vaccinated over 10 lakh beneficiaries of the age group 18-44 years for the first dose of COVID-19 vaccine, the ministry said.

As on day-206 of the vaccination drive (August 9), 49,06,273 vaccine doses were given.

The ministry said 36,80,340 beneficiaries were vaccinated for first dose and 12,25,933 beneficiaries received second dose of vaccine as per the provisional report till 7 PM.

Final reports would be completed for the day by late night.

The vaccination exercise as a tool to protect the most vulnerable population groups in the country from COVID-19 continues to be regularly reviewed and monitored at the highest level, it stated.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineHealth Ministryclinical trials

First Published: Aug 09 2021 | 9:59 PM IST

Next Story